Story perspectives

39.9% of Breast Cancer Patients Face Chemobrain Challenges

10/15/2025

46 9

Summary

Story summary

The meta-analysis finds 39.9% of breast cancer patients undergoing chemotherapy experience chemobrain.
There is no consensus on defining or measuring chemobrain, with 11 articles using varied tools.
The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) is the most utilized self-report tool.
Researchers say docetaxel may disrupt the brain’s lymphatic system, contributing to cognitive issues.
Ongoing studies aim to develop interventions and emphasize the need for standardized definitions and management.

1 of 1

Story summary

The meta-analysis finds 39.9% of breast cancer patients undergoing chemotherapy experience chemobrain.
There is no consensus on defining or measuring chemobrain, with 11 articles using varied tools.
The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) is the most utilized self-report tool.
Researchers say docetaxel may disrupt the brain’s lymphatic system, contributing to cognitive issues.
Ongoing studies aim to develop interventions and emphasize the need for standardized definitions and management.